InMed Pharmaceuticals Statistics
Share Statistics
InMed Pharmaceuticals has 1.21M
shares outstanding. The number of shares has increased by -85.56%
in one year.
| Shares Outstanding | 1.21M |
| Shares Change (YoY) | -85.56% |
| Shares Change (QoQ) | 66.7% |
| Owned by Institutions (%) | 0% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,848 |
| FTD / Avg. Volume | 4.6% |
Short Selling Information
The latest short interest is 43.54K, so 3.61% of the outstanding
shares have been sold short.
| Short Interest | 43.54K |
| Short % of Shares Out | 3.61% |
| Short % of Float | 3.62% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -4.99 and the forward
PE ratio is null.
InMed Pharmaceuticals's PEG ratio is
0.07.
| PE Ratio | -4.99 |
| Forward PE | n/a |
| PS Ratio | 8.34 |
| Forward PS | 0 |
| PB Ratio | 4.16 |
| P/FCF Ratio | -5.48 |
| PEG Ratio | 0.07 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for InMed Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.41,
with a Debt / Equity ratio of 0.1.
| Current Ratio | 4.41 |
| Quick Ratio | 3.78 |
| Debt / Equity | 0.1 |
| Debt / EBITDA | -0.14 |
| Debt / FCF | -0.14 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $353,671.54 |
| Profits Per Employee | $-590,426.92 |
| Employee Count | 13 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 2.81 |
Taxes
| Income Tax | 7.1K |
| Effective Tax Rate | -0.09% |
Stock Price Statistics
The stock price has increased by -46.64% in the
last 52 weeks. The beta is 0.47, so InMed Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.47 |
| 52-Week Price Change | -46.64% |
| 50-Day Moving Average | 2.69 |
| 200-Day Moving Average | 4.17 |
| Relative Strength Index (RSI) | 54.03 |
| Average Volume (20 Days) | 40,138 |
Income Statement
In the last 12 months, InMed Pharmaceuticals had revenue of 4.6M
and earned -7.68M
in profits. Earnings per share was -1.01.
| Revenue | 4.6M |
| Gross Profit | 1.1M |
| Operating Income | n/a |
| Net Income | -7.68M |
| EBITDA | -7.06M |
| EBIT | -8.13M |
| Earnings Per Share (EPS) | -1.01 |
Full Income StatementBalance Sheet
The company has 6.57M in cash and 962.66K in
debt, giving a net cash position of 5.61M.
| Cash & Cash Equivalents | 6.57M |
| Total Debt | 962.66K |
| Net Cash | 5.61M |
| Retained Earnings | -109.08M |
| Total Assets | 8.5M |
| Working Capital | -1.79B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -6.99M
and capital expenditures -9.29K, giving a free cash flow of -7M.
| Operating Cash Flow | -6.99M |
| Capital Expenditures | -9.29K |
| Free Cash Flow | -7M |
| FCF Per Share | -0.92 |
Full Cash Flow StatementMargins
Gross margin is 23.94%, with operating and profit margins of 0% and -166.94%.
| Gross Margin | 23.94% |
| Operating Margin | n/a |
| Pretax Margin | -166.79% |
| Profit Margin | -166.94% |
| EBITDA Margin | -153.64% |
| EBIT Margin | n/a |
| FCF Margin | -152.14% |
